Curing a blood cancer with someone else's stem cells has always carried a second bill. The donated immune system, doing what immune systems do, can turn on the body it now lives in. Chronic graft-versus-host disease is that turning: stiffened skin, dry destroyed eyes, damaged lungs and gut, years of immunosuppression, for people who already survived leukemia to get there. It is the reason transplant survivors talk about being cured in a complicated tone of voice.
The FDA has approved Tregzi, the first regulatory T-cell immunotherapy, for adults undergoing matched-donor stem cell transplants for blood cancers. Regulatory T cells are the immune system's brakes, the cells whose job is telling other immune cells to stand down. The therapy engineers a graft that carries them deliberately. [1][2]
In PRECISION-T, the randomized trial of 187 patients behind the approval: at one year, 78 percent of patients who received Tregzi were alive and free of chronic GVHD, against 38.4 percent of those who got the standard transplant plus tacrolimus and methotrexate. [1] Roughly double. Serious chronic GVHD occurred in 12.6 percent versus 44 percent. [1] The sponsor's release adds the rest of the picture: overall survival 94 percent versus 83 percent, GVHD-free and relapse-free survival 63 percent versus 31 percent, non-relapse mortality 3 percent versus 13 percent. [2] Safety was, in the FDA's characterization, generally consistent with what transplant patients already face, most commonly infections, with no severe infusion reactions or graft failures reported. [2]
One housekeeping note about dates, since both are official: Orca Bio states the approval came June 30; the FDA's own announcement is dated July 1. We report both rather than pick. The therapy holds Orphan Drug and Regenerative Medicine Advanced Therapy designations. [2]
What these numbers mean at human scale: in a hundred people getting a transplant the old way, about 38 reach the one-year mark without the chronic disease. With this, about 78 do. Forty more people, per hundred, walk into their second year with the cure and not the tax on it. Dr. Miguel-Angel Perales of Memorial Sloan Kettering called it "a new era in transplant medicine." For the 187 people in that trial, and everyone who follows them, it is more specific than an era. It is the difference between surviving cancer and surviving the treatment.
